According to TipRanks.com, Block is a 4-star analyst with an average return of 5.2% and a 49.7% success rate. Block covers the Healthcare sector, focusing on stocks such as Inspire Medical Systems, ...

The American Cancer Society (ACS) today announced a new partnership with Guardant Health (Nasdaq: GH), a leading precision ...

A groundbreaking study reveals that Guardant Reveal's liquid biopsy detects immunotherapy responses earlier, enhancing ...

Second Quarter 2025 Results Key Financial Results Revenue: US$232.1m (up 31% from ...

James Van Der Beek and Guardant are partnering for a campaign focused on colorectal cancer. Guardant Health announced a ...

James Van Der Beek was diagnosed with colon cancer in 2023. He hopes more people will get screened earlier with the new ...

Guardant Health raised its FY2025 sales guidance from $880.00 million-$890.00 million to $915.00 million-$925.00 million.

Guardant Health reports strong Q2 2025 results with 31% revenue growth, raised guidance, and momentum in oncology and Shield screening.

Van Der Beek offered a reminder that colorectal cancer is one of the most curable types of cancer when it’s caught early and ...

Diagnostics company Guardant Health (NASDAQ:GH) in Q2 CY2025, with sales up 30.9% year on year to $232.1 million. The company ...

Guardant Health (GH) came out with a quarterly loss of $0.44 per share versus the Zacks Consensus Estimate of a loss of $0.52. This compares to a loss of $0.48 per share a year ago. These figures are ...

PALO ALTO, Calif. (AP) — PALO ALTO, Calif. (AP) — Guardant Health Inc. (GH) on Wednesday reported a loss of $99.9 million in its second quarter. The Palo Alto, California-based company said it had a ...